Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cizolirtine is a small molecule pyrazole derivative originally developed by Esteve Pharmaceuticals for the treatment of various pain conditions and urinary incontinence secondary to overactive bladder. Its mechanism of action involves the modulation of neuropeptide release, specifically inhibiting the presynaptic release of substance P (SP) and calcitonin gene-related peptide (CGRP) at the spinal cord level. This inhibitory effect is mediated through an alpha-2 adrenoceptor-dependent pathway. Clinical development reached Phase II and Phase III for indications including neuropathic pain, renal colic, cancer pain, and diabetic neuropathy, as well as overactive bladder. However, the global research and development for cizolirtine has been discontinued.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cizolirtine.